

Section 1.3 on page 3

Does CVAD anticipate sending the 200-250 priority SAKs to a single vendor or to multiple vendors?

**It depends on the capacity of the vendor labs to handle expedited processing and the price to do so.**

Section 4.3.1.3 on page 20

Is it acceptable to use a different quant kit that has been fully validated in the vendor's laboratory and found to be more reliable when DTT is used during extraction?

**No. Quant Trio must be used as that is the kit used at the Iowa DCI Crime Lab.**

Section 4.1 on page 29 and Attachment 4 on page 53

Should the RFP response also include a price for sample amplification? Or, will every Y-screen positive sample be amplified with GlobalFiler?

**A price for sample amplification should be included. This is what section 4.1.2 on page 29 is asking for.**

Section 1.15 on page 42

Please describe what is meant by "secondary evidence."

**These are items included in the kit that would not be routinely in a standard kit. Examples may include: a) condom b) tampon c) speculum.**

Section 2.1.21 on page 46

Is CPI an acceptable statistical calculation for indiscernible mixtures?

**No.**

Section 1.3. and 1.4 on pages 41 and 54

The turnaround times differ between these two pages (15 and 75 days versus 30 and 90 days, respectively). Which is correct?

**30 and 90 days.**

Section 2.1.37

Can the chain of custody be returned with, or at the same time as, the evidence and extracts rather than with the case file so it will be complete?

**Yes, chain of evidence gets returned to the jurisdictional law enforcement agency. The case file is sent separately to the DCI crime laboratory. No chain of custody is needed for the case file.**

What is the term of the contract including the number of renewal years?

**April 24, 2017 – September 30, 2018 with up to 5 one year renewals.**

Are Offerors at liberty to offer either expedited or non-expedited services and still be considered responsive or are both service offerings required?

**We would accept one or both offerings.**

Please confirm that we are correct in our understanding that the term “day” or “days” refers to work days or business days unless otherwise specified.

**Yes, business days. Weekends and Holidays are not counted.**

Regarding section 6.2 on page 35, is it equally acceptable to the agency to be listed as certificate holder on the certificate of insurance rather than additional insured?

**Yes**

Please confirm that all clauses in Attachment 3 are present and in the correct order regardless of numbering?

**There is an error in the paragraph numbering of the contract, which is Attachment 3. Other than the error in the paragraph numbering, the contract is complete and is in correct order.**

On page three (3) and elsewhere in the RFP we find discussion of the requirement that the service provider complete testing of cases that require expedited services within 20 days and then provide final results within 35 days of the time the SAK was received.

Are we correct to assume that the time required for the reviewing lab to evaluate results will not be counted against either the 20 or 35 days testing/reporting windows allowed the service provider?

**Yes**

In the event that no changes or corrections are requested after review, is the report which is required to be submitted to the reviewing entity after 20 days the same as the final report which is reported after 35 days. If different, please describe how they differ.

**They are the same.**

Section 2.1.9 indicates that Y-screen testing is necessary for up to 10 samples per SAK. A typical SAK includes fewer samples and most common items are vaginal swabs, anal swabs, oral swabs and body swabs. Are there additional samples in a typical SAK?

**No there are not additional samples in a typical SAK. As an example, we are counting 2 vaginal swabs, 2 anal swabs, 2 oral swabs, 2 breast swabs, and 2 bite mark swabs all in one SAK as 10 samples.**

Please describe what constitutes “secondary evidence”. Section 1.15 states that these are ‘a separate submission’. Does that mean that they will follow a turnaround time separate from the primary evidence? Additionally, if secondary evidence includes items of clothing or other large items, we request additional line items on the Cost Proposal Form.

**The secondary evidence that we are referring to would be inside of the SAK and not clothing or other large items. Examples may include: a) condom b) tampon c) speculum. In this situation the turnaround time would be expected to be the same as for the swabs normally included inside of the SAK.**

If there are fewer than 10 items of swab evidence in the kit, will the vendor be required to process “secondary evidence” or will the testing be limited to the swab evidence?

**Yes, the vendor will be required to process the secondary evidence. Examples of such evidence would be the same as listed above.**

Since CODIS eligibility requirements vary for state to state, will the reviewing lab determine which samples meet the requirements for CODIS?

**The DCI Crime laboratory will have the final decision if a profile will be entered into CODIS. However, we expect the vendor laboratory to make an assessment if the profile developed is a candidate for CODIS entry based upon the patient information sheet, which will be included in the SAK, and the statistical frequency of the profile developed.**

Will the reviewing lab provide the monthly reports of the service provider’s work activity?

**We expect the reviewing lab and the vendor lab to provide monthly reports of their own work activity.**

Please provide guidance on the following topics as they relate to Attachment 4 Cost Proposal Form on page 53:

**No, we would like a cost per SAK. Question 7B (1-4) are not applicable based upon our answer to question 7A.**

- a. Are we correct in our understanding that “test” means an individual sample or item of evidence?
- b. The 4 categories listed do not appear to capture all of the possible scenarios.
  1. For the description ‘Each Y-screen positive test’, does that include all samples that are Y-screen positive and taken forward for STRs?
  2. What about samples that are Y-screen positive but not taken forward for STRs?

3. For expedited testing, the only category are Y-screen positive tests. What about Y-screen negative and Y-screen positive which don't proceed to STRs?
  4. For secondary items, there is only 1 scenario. For these items, we request the addition of line items for Y-screen negative and Y-screen positive which don't proceed to STRs. Also, pricing for expedited testing of secondary items should be included as well.
8. Please provide examples of what additional metrics might be required by DCI Crime Lab as referenced in section 1.13 (3) pg 55 of RFP.

**Upon review of the question, at this time the DCI Crime Lab has not identified any additional metrics.**